AstraZeneca Cuts Drug Prices, Invests $50B in U.S.

AstraZeneca and the Shift in U.S. Pharmaceutical Pricing

A major development has taken place in the U.S. pharmaceutical sector, with British global pharmaceutical company AstraZeneca announcing an agreement to lower drug prices under the administration of former U.S. President Donald Trump. This move follows a similar deal made with Pfizer, marking a significant shift in how pharmaceutical companies are responding to pressure from the government.

On the 10th of last month, Trump announced the agreement at the White House, stating that AstraZeneca would supply all prescription drugs to Medicaid, which serves low-income individuals, at the most-favored-nation (MFN) price. The MFN price refers to the lowest price that pharmaceutical companies offer to developed countries outside the U.S. In addition to this, AstraZeneca agreed to sell all medicines launched in the U.S. market at discounted prices and invest $50 billion in the U.S. over the next five years. As part of the deal, the company will be exempt from pharmaceutical tariffs for three years.

This is not the first time AstraZeneca has committed to such an investment. Earlier in July, the company had already announced its plan to invest $50 billion in the U.S. by 2030 for pharmaceutical manufacturing and research and development, amid increasing tariff pressures from the Trump administration. The investment includes a $4.5 billion commitment to expand manufacturing facilities in Virginia, creating 3,600 jobs. This plan involves building a new drug manufacturing facility in Virginia and expanding R&D and manufacturing operations in several states, including Maryland, Massachusetts, California, Indiana, and Texas. The facility will focus on producing raw pharmaceuticals for obesity and metabolic diseases, including GLP-1, as well as manufacturing anticancer drugs like antibody-drug conjugates (ADCs). It is expected to become operational within 4–5 years.

AstraZeneca CEO Pascal Soriot highlighted the significance of the investment, stating, “By investing $4.5 billion, the largest in AstraZeneca’s history, in Virginia, we will build a state-of-the-art manufacturing facility.” He added, “This facility will create thousands of jobs and strengthen U.S. national security and health sovereignty.”

The Broader Trend of Pharmaceutical Companies Investing in the U.S.

Pfizer was among the first to announce plans to invest in the U.S., committing $70 billion (approximately 98 trillion Korean won) to manufacture pharmaceuticals. Like AstraZeneca, Pfizer also reached an agreement with the U.S. government to sell new drugs launched in the U.S. at MFN prices, in exchange for a three-year tariff exemption on pharmaceuticals.

The trend of pharmaceutical companies investing heavily in the U.S. has continued, with other global players also under pressure to respond to the Trump administration's "tariff policy." These companies are not only announcing large-scale investments to build and expand U.S. manufacturing facilities but are also under pressure to reduce drug prices.

For instance, U.S.-based Eli Lilly recently announced plans to build a $5 billion (approximately 6.9 trillion Korean won) manufacturing facility in Goochland County, Virginia. This marks the first concrete step in four planned manufacturing plant construction projects announced earlier this year. The facility, expected to be completed within the next five years, is projected to create over 650 jobs in Virginia, including positions for scientists and technicians.

Swiss global pharmaceutical company Novartis also announced in April plans to invest $23 billion (approximately 32 trillion Korean won) over five years to expand manufacturing and R&D facilities in the U.S. Similarly, another Swiss pharmaceutical company, Roche, announced in April plans to invest $50 billion (approximately 71 trillion Korean won) in the U.S. over the next five years. U.S.-based MSD has stated plans to invest $1 billion to enhance domestic vaccine production capabilities, while Johnson & Johnson has outlined plans to invest $55 billion in domestic manufacturing.

Conclusion

The growing trend of pharmaceutical companies investing in the U.S. reflects the broader impact of the Trump administration's policies on the industry. With increased pressure to reduce drug prices and invest in domestic manufacturing, companies are reevaluating their strategies to align with the new economic landscape. This shift not only affects the pharmaceutical sector but also has implications for employment, healthcare access, and the overall economy.